雷达财经 文|杨洋 编|李亦辉 在业绩方面，公司2022年至2024年营业收入分别为86.94亿元、100.58亿元和107.88亿元，同比分别增长8.38%、15.69%和7.25%。归母净利润分别为24.72亿 元、27.97亿元和29.77亿元，归母净利润同比增长分别为1.66%、13.15%和6.42%。同期，公司资产负债率分别为19.04%、18.50%和15.40%。 在风险方面，天眼查信息显示，公司自身天眼风险108条，周边天眼风险273条，历史天眼风险4条，预警提醒天眼风险423条。 天眼查资料显示，片仔癀成立于1999年12月28日，注册资本60331.721万人民币，法定代表人林志辉，注册地址为福建省漳州市芗城区琥珀路1号。主营业务 为医药制造业、医药流通业及化妆品业等。 目前，公司董事长为林志辉，董秘为施艺雄，员工人数为2839人，实际控制人为漳州市人民政府国有资产监督管理委员会。 公司参股公司55家，包括福建片仔癀电子商务有限公司、漳州片仔癀投资管理有限公司、福建片仔癀健康科技有限公司、片仔癀电商国际贸易（香港）有限 公司、漳州片仔癀国药堂医药连锁有限公司等。 5月30日，漳州片公告， ...

证券代码：600436 证券简称：片仔癀 公告编号：2025-017 本次投资招盈慧康基金，经公司第七届董事会第二十七次会议以 及第七届监事会第十九次会议审议通过（详见公告2025-005、006号）。 二、对外投资进展 漳州片仔癀药业股份有限公司 关于投资参与招盈慧康基金的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、对外投资概述 漳州片仔癀药业股份有限公司（以下简称"公司"）全资子公司 漳州片仔癀投资管理有限公司（以下简称"片仔癀投资"）与招商致 远资本投资有限公司（以下简称"基金管理人"）、漳州市产业股权 投资有限公司、漳州片仔癀资产经营有限公司、漳州市旅游投资集团 有限公司、漳州台商投资区资产运营集团有限公司共同发起设立漳州 台商投资区招盈慧康股权投资合伙企业（有限合伙）（以下简称"招 盈慧康基金"）。其中，片仔癀投资作为有限合伙人以自有资金认缴 出资20,000万元，占招盈慧康基金的比例为20.00%。 本次投资招盈慧康基金，为公司战略发展的前瞻性布局。在保证 公司主营业务稳健发展的前提下，以基金投资 ...

Core Viewpoint - The company, Pianzaihuang Pharmaceutical Co., Ltd., reported a solid performance in 2024, achieving a consolidated revenue of approximately 10.788 billion yuan, a year-on-year increase of 7.25%, and a net profit attributable to shareholders of about 2.977 billion yuan, up 6.42% from the previous year [4][5][6]. Group 1: Meeting Procedures and Governance - The 2024 Annual General Meeting (AGM) will be held on June 20, 2025, at 09:00, at the Zhangzhou Xiangjiang Hotel [3]. - The meeting will include a verification of the identity of attendees, and shareholders will have the right to speak, inquire, and vote [2][3]. - Voting will be conducted by registered ballot, with each share representing one vote [2][3]. Group 2: Business Performance - The company achieved a consolidated revenue of approximately 10.788 billion yuan in 2024, representing a 7.25% increase year-on-year [4]. - The net profit attributable to shareholders was about 2.977 billion yuan, reflecting a 6.42% increase compared to the previous year [4]. - The company paid approximately 14 billion yuan in cash dividends, accounting for 50.04% of the net profit attributable to shareholders [9]. Group 3: Honors and Recognition - The company was recognized as one of the "Top 100 Enterprises in Comprehensive Competitiveness of Traditional Chinese Medicine Industry" and received multiple awards for its brand value and cultural heritage [5][6]. - The company ranked first in the market capitalization of the traditional Chinese medicine industry, with a market value exceeding 120 billion yuan [6]. - The company received various awards, including the "2023 Golden Bull Most Investment Value Award" and "2024 Top 20 ESG Competitiveness in Chinese Pharmaceutical Listed Companies" [6]. Group 4: Research and Development - The company is focusing on enhancing its independent innovation capabilities, with ongoing clinical research on 14 new drug projects [12][13]. - The company has established partnerships with over 10 academicians for collaborative projects, aiming to accelerate technological breakthroughs [13]. - The company is actively involved in national key research projects, enhancing its research capabilities in traditional Chinese medicine [13][14]. Group 5: Future Plans - The company plans to increase its new drug projects and clinical research initiatives, aiming to launch 2-3 new drug projects in the coming year [21]. - The company will focus on expanding its market presence in traditional medicine channels and new consumer markets [21]. - The company aims to enhance its brand visibility through new media and targeted marketing strategies [21].

证券代码：600436 证券简称：片仔癀 公告编号：2025-016 漳州片仔癀药业股份有限公司 关于召开2024年年度股东大会的通知 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 至2025 年 6 月 20 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投 票时间为股东大会召开当日的交易时间段， 即 9:15-9:25,9:30-11:30， 无。 非累积投票议案 《公司关于聘任会计师事务所及确定其报酬事项 的议案》 《公司 2024 年度财务决算及 2025 年度财务预算 报告》 《公司 2025 年度董事、监事、高级管理人员薪酬 额度的议案》 本次股东大会还将分别听取各位独立董事《公司 2024 年度独立 董事述职报告》 。 上述议案已经公司第七届董事会第二十八次会议和第七届监事 会第二十次会议审议通过，相关决议公告及文件已按照规定和要求在 上海证券交易所网站（www.sse.com.cn）及公司选定的中国证监会指 二、 会议审议事项 本次股东大会审议议案及投票股东类型 | | | 投票股 ...

证券代码：600436 证券简称：片仔癀 公告编号：2025-016 漳州片仔癀药业股份有限公司 关于召开2024年年度股东大会的通知 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、 召开会议的基本情况 (一) 股东大会类型和届次 2024年年度股东大会 召开的日期时间：2025 年 6 月 20 日 09 点 00 分 召开地点：漳州市芗城区漳州芗江酒店二楼芝山厅 1 股东大会召开日期：2025年6月20日 本次股东大会采用的网络投票系统：上海证券交易所股东大 会网络投票系统 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自2025 年 6 月 20 日 至2025 年 6 月 20 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投 票时间为股东大会召开当日的交易时间段，即9:15-9:25,9:30-11:30， 13:00-15:00；通过互联网投票平台的投票时间为股东大会召开当日 的 9:15-15:00。 (六) 融资融券、转融通、约定购回业务账户和沪股通投资者 ...

股票代码：600436 股票简称：片仔癀 漳州片仔癀药业股份有限公司 2024 年年度股东大会会议材料 福建·漳州 二〇二五年六月二十日 0 漳州片仔癀药业股份有限公司 2024 年年度股东大会会议材料 漳州片仔癀药业股份有限公司 2024 年年度股东大会事项、表决方法说明 各位股东、股东代表： 根据中国证券监督管理委员会《上市公司股东会规则》和《漳州片仔 癀药业股份有限公司章程》（以下简称"《公司章程》"）等有关规定， 公司 2024 年年度股东大会会议事项、投票表决等规定如下： 一、为确认出席大会的股东或其代理人或其他出席者的出席资格，会议 工作人员将对出席会议者的身份进行必要的核对，请被核对者给予配合。 二、股东及股东代表应于会议开始前入场；中途入场者，应经会议工作 人员的许可。 三、股东参加股东大会依法享有发言权、质询权、表决权等权利。股东 参加股东大会应认真履行其法定义务，不得侵犯公司和其他股东的合法权 益，不得扰乱股东大会的正常秩序。 四、要求发言的股东，应当按照会议的议程，经会议主持人许可方可发 言。有多名股东同时要求发言时，先举手者发言；不能确定先后时，由主 持人指定发言者。会议进行中只接受股 ...

Group 1 - The Shanghai Composite Index opened high and fluctuated, with the CSI 300 Pharmaceutical and Biotechnology Index reported at 7798.06 points [1] - The CSI 300 Pharmaceutical and Biotechnology Index has increased by 4.26% in the past month, 2.71% in the past three months, and 4.75% year-to-date [1] - The CSI 300 Index samples are categorized into 11 primary industries, 35 secondary industries, over 90 tertiary industries, and more than 200 quaternary industries [1] Group 2 - The top ten weights in the CSI 300 Pharmaceutical and Biotechnology Index are: Heng Rui Medicine (25.23%), WuXi AppTec (16.45%), Pian Zai Huang (6.51%), Yunnan Baiyao (5.3%), Kelun Pharmaceutical (5.04%), East China Pharmaceutical (3.91%), New Horizon (3.59%), Changchun High-tech (3.57%), Shanghai Raist (3.34%), and Fosun Pharmaceutical (3.18%) [1] - The market share of the CSI 300 Pharmaceutical and Biotechnology Index is 63.57% from the Shanghai Stock Exchange and 36.43% from the Shenzhen Stock Exchange [2] - The industry composition of the index includes: Chemical drugs (43.24%), Pharmaceutical and Biotechnology services (21.56%), Traditional Chinese medicine (18.83%), and Biological drugs (16.37%) [2] Group 3 - The index samples are adjusted every six months, with adjustments implemented on the next trading day after the second Friday of June and December each year [2] - Weight factors are generally fixed until the next scheduled adjustment, with temporary adjustments made when the CSI 300 Index samples are modified [2] - Special events affecting sample companies may lead to changes in industry classification and subsequent adjustments to the CSI 300 industry index samples [2]

证券研究报告 | 金融工程 2025 年 05 月 24 日 刚需+出海+历史低位，多重因素凸显制药价值 ——华宝中证制药 ETF 投资价值分析 随着保健意识的提升及国内人口老龄化趋势的发展，药品作为人们生活中的刚 性需求，其市场需求量日益增长。从供给端来看，原研药专利集中到期，创新 药频获出海订单，中药受政策大力扶持，各细分领域药企均迎来发展机遇。时 逢相关标的位于历史的价格低位，药品制造业显示出一定的投资机会。华宝中 证制药 ETF（认购代码：562053.OF）通过紧密跟踪中证制药指数，一键式配 置制药行业优质上市企业，值得投资者关注。 任瞳 S1090519080004 rentong@cmschina.com.cn ❑ 风险提示：本报告仅作为投资参考，基金产品过往业绩并不预示其未来表 现，亦不构成投资收益的保证或投资建议，新发基金无历史业绩可参考。 敬请阅读末页的重要说明 专题报告 ❑ 在新兴市场经济快速发展和各国医疗保障制度的逐渐完整之下，全球医药 市场规模仍旧维持着稳定增长态势。而据统计，我国的人均药品用量仍远 低于世界发达国家水平，国内药品用量的需求增长仍然具有较大的空间。 ❑ 在供给端，各细 ...

Core Viewpoint - On May 19, 39 target price adjustments were made by brokerages for listed companies, with notable increases in target prices for Kun Pharmaceutical Group, Yongxi Electronics, and Taotao Vehicle, reflecting significant growth potential in the traditional Chinese medicine, semiconductor, and motorcycle industries respectively [1][2]. Group 1: Target Price Increases - Kun Pharmaceutical Group saw a target price increase of 55.14%, with a latest rating of "Buy" from Huatai Financial Holdings (Hong Kong) [2]. - Yongxi Electronics experienced a target price increase of 47.45%, rated "Buy" by CITIC Securities [2]. - Taotao Vehicle's target price rose by 46.25%, also rated "Buy" by Huatai Financial Holdings (Hong Kong) [2]. Group 2: Brokerage Recommendations - A total of 86 listed companies received brokerage recommendations on May 19, with Tongwei Co. receiving recommendations from 4 brokerages, and Huasheng Group and Kunlun Wanwei each receiving 2 recommendations [2]. - The highest number of recommendations indicates strong interest and confidence in these companies within their respective sectors [2]. Group 3: Rating Adjustments - On May 19, there was one upgrade in ratings, with Huachuang Securities raising the rating for Tianwei Food from "Recommended" to "Strongly Recommended" [3]. - There were two downgrades, including Huachuang Securities lowering the rating for BioShares from "Strongly Recommended" to "Recommended," and Huatai Securities downgrading Tongwei Co. from "Buy" to "Increase" [3]. Group 4: First-Time Coverage - On May 19, 12 companies received first-time coverage, including Semir Apparel and Bright Dairy, which were rated "Increase" by Industrial Securities [4]. - Other companies like Wens Foodstuffs received a "Buy" rating, indicating a positive outlook for these newly covered firms [4].

Company Overview - Weifang Tongzhitang Pharmaceutical Co., Ltd. operates a Pi Zai Huang experience center in Weifang, affiliated with Fujian Zhangzhou Pi Zai Huang Pharmaceutical Co., Ltd. It is the sole partner in the Weifang region, offering a range of products under the Pi Zai Huang brand, including Pi Zai Huang, Pi Zai Huang capsules, and various health and skincare products [3][4]. Product Offerings - The main ingredients of Pi Zai Huang include Niu Huang, She Xiang, San Qi, and She Dan, which are known for their effects in clearing heat and detoxifying, cooling blood and resolving stasis, and alleviating pain. It is used for conditions such as viral hepatitis, abscesses, and various inflammations [6]. - Pi Zai Huang capsules serve the same purpose as the traditional tablets, designed for convenience for travelers who may find it difficult to carry the original form [6]. - An Gong Niu Huang Wan is effective in clearing heat and detoxifying, used for high fever, convulsions, and various severe conditions. It is recommended for middle-aged individuals under stress, those with unhealthy lifestyles, and those with a family history of cardiovascular diseases [8]. - The company offers two main types of bird's nest products: Bai Yan Zhan and ready-to-eat bird's nest, sourced from Indonesia and Malaysia, ensuring purity and quality through advanced production techniques [10]. - Skincare products are categorized into anti-aging, whitening, hydration, and acne treatment, adhering to pharmaceutical-grade standards and available in both individual and gift sets [12].